Abstract:Background: Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion. Objective: Our study highlights the impact of Irinotecan on gut microbiota composition and the role of probiotics in limiting Irinotecan-associated diarrhea and suppressing gut bacterial β-glucuronidase enzymes. Material and methods: To investigate the effect of Irinotecan on the gut microbiota composition, we applied 16S rRNA gene sequencing in three groups of stool samples from healthy individuals, colon cancer, and Irinotecan treated patients (n = 5/group). Furthermore, three Lactobacillus spp.; Lactiplantibacillus plantarum (L. plantarum), Lactobacillus acidophilus (L. acidophilus), Lacticaseibacillus rhamnosus (L. rhamnosus) were used in a single and mixed form to in-vitro explore the effect of probiotics on the expression of β-glucuronidase gene from E. coli. Also, probiotics were introduced in single and mixed forms in groups of mice before the administration of Irinotecan, and their protective effects were explored by assessing the level of reactive oxidative species (ROS) as well as studying the concomitant intestinal inflammation and apoptosis. Results: The gut microbiota was disturbed in individuals with colon cancer and after Irinotecan treatment. In the healthy group, Firmicutes were more abundant than Bacteriodetes, which was the opposite in the case of colon-cancer or Irinotecan treated groups. Actinobacteria and Verrucomicrobia were markedly present within the healthy group, while Cyanobacteria were noted in colon-cancer and the Irinotecan-treated groups. Enterobacteriaceae and genus Dialister were more abundant in the colon-cancer group than in other groups. The abundance of Veillonella, Clostridium, Butryicicoccus, and Prevotella were increased in Irinotecan-treated groups compared to other groups. Using Lactobacillus spp. mixture in mice models significantly relieved Irinotecan-induced diarrhea through the reduction of both β-glucuronidase expression and ROS, in addition to guarding gut epithelium against microbial dysbiosis and proliferative crypt injury. Conclusions: Irinotecan-based chemotherapy altered intestinal microbiota. The gut microbiota participates greatly in determining both the efficacy and toxicity of chemotherapies, of which the toxicity of Irinotecan is caused by the bacterial ß-glucuronidase enzymes. The gut microbiota can now be aimed and modulated to promote efficacy and decrease the toxicity of chemotherapeutics. The used probiotic regimen in this study lowered mucositis, oxidative stress, cellular inflammation, and apoptotic cascade induction of Irinotecan.

Research Progress on Irinotecan Induced Metabolic Dysregulation in Microbiota-Gut-liver Axis and Chinese Materia Medica Intervention

Mechanisms and Emerging Strategies for Irinotecan-Induced Diarrhea

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Intestinal Toxicity of Irinotecan and Its Clinical Prevention

Plasma metabonomic study on glycyrrhiza flavonoids against irinotecan-induced colitis in mice based on GC-MS

Insight into the Mechanism of Xiao-Chai-Hu-Tang Alleviates Irinotecan-Induced Diarrhea Based on Regulating the Gut Microbiota and Inhibiting Gut β-GUS

Targeting the Gut Microbiota to Alleviate Chemotherapy-Induced Toxicity in Cancer

Research progress on the effect of gut and tumor microbiota on antitumor efficacy and adverse effects of chemotherapy drugs

The efficacy and toxicity of antineoplastic antimetabolites: Role of gut microbiota

Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management

Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors

Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach.

The effective combination therapies with irinotecan for colorectal cancer

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis

The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review

Systematic Evaluation Of Therapeutic Efficacy And Safety Of Traditional Chinese Medicine Injection (Tcmi) Combined With Oxaliplatin-Containing Chemotherapy In The Treatment Of Colorectal Cancer

Efifcacy and Predictive Molecule Markers Associated Toxicity of Irinotecan for Colorectal Cancer

A Fatal Myelosuppression, Diarrhea and Neurotoxicity Induced by Combination of Irinotecan and Tegafur-Gimeracil-oteracil Potassium in the Treatment of Colon Cancer: a Case Report

Research progress of intestinal microbiota in targeted therapy and immunotherapy of colorectal cancer

Metabolomic Study of Chinese Medicine Huang Qin Decoction As an Effective Treatment for Irinotecan-Induced Gastrointestinal Toxicity